Overview
Stereotactic body radiotherapy (SBRT) has emerged as an effective and safe treatment for low and intermediate-risk prostate cancer(PCa). However, there is no study that has investigated the effectiveness and safety of SBRT with pelvic radiation and gross target volume(GTV) boost for high-risk prostate cancer patients yet. The investigators designed a phase II clinical study of SBRT with pelvic radiation and GTV boost based on mpMRI in patients with high-risk prostate cancer.
Eligibility
Inclusion Criteria:
- 18 years or older
- pathologically confirmed high-risk (T3a or Gleason score ≥ 8 or a PSA > 20 ng/ml) prostate cancer
- a WHO performance status 0-1
- history of neoadjuvant androgen deprivation therapy(ADT) within 6 months before enrollment
- Patients with pelvic positive lymph node were also included in our study
Exclusion Criteria:
- distant metastasis
- history of neoadjuvant ADT over 6 months before enrollment
- history of definitive treatment for prostate cancer such as radical prostatectomy
- history of pelvic irradiation; prostate volume≥100 cm3